Presentation from MoneyTalks, 13.03.2012, by StatFinn.

1. Innovative reporting engines
from
StatFinn Ltd
The fastest way to conclusion www.statfinn.fi
www.statfinn.fi

2. Market Opportunity
The Drug Deveopment Challenge
 Pharma has, on average, 12 patent protected years to recover
massive amount of development costs (up to $2 billion) and to
make profit.
 For a blockbuster drug each day saved in development means
one extra day in market which is extra $15 million in sales.
 Consequently drug developing companies are desperate for finding
tools and services that could shorten the development phase
and time-to-market.
3.5 years 4 years 2-4 years
$ 350 million $ 100 million $ 150 million
Preclinical Exploratory Full
Discovery Launch
Development Development Development
Phase I Phase II Phase III Phase IV
Preclinical Clinical
The fastest way to conclusion

3. Solution
Innovative Approach
StatFinn provides data management and statistical
reporting services to pharmaceutical industry.
StatFinn’s eBESTreports is first-in-market reporting
application for the time and resources consuming reporting
phase of clinical trials.
 eBESTreports is available 24-7 as a cloud service and
reduce the reporting time remarkably.
The fastest way to conclusion

4. Business Model
From expert services to productized services
 eBESTreports is used as arrow-head product to increase revenues
of StatFinn’s traditional services.
 eBESTreports is highly profitable needing
minimal resources from StatFinn.
CRO Products
 eBESTreports are easily scaled up with
additional service products.
 Target sectors Biotech, Pharma and Custom
clinical CROs companies.
 CRO companies act as distributors INITIAL SALES
while using the tool to Biotech and Pharma.
The fastest way to conclusion

5. Markets
Growing quickly
 The total CRO market is $35 billion by 2015.
 Annual growth of 11%.
 Market potential for StatFinn services is $1 billion.
The fastest way to conclusion

6. Financial Projections
Year 2016
Revenue 10 M€ Products 25% People 35
 Customers:  Increases sales  Finland 25,
15 Pharma, 70 Biotechs, of all services Switzerland 5,
10 CROs UK/Germany 5
 Profit 30%
 International business 80%  Business acquisitions
16.000.000 €
14.000.000 € Sales
12.000.000 €
10.000.000 € Profit
8.000.000 €
6.000.000 €
4.000.000 €
2.000.000 €
0€
2011 2012 2013 2014 2015 2016 2017
The fastest way to conclusion

7. The Team
The Company
Pekka Heikkilä (15%), Pasi Korhonen (60%),
CEO, Member of Board Founder, CSO, Chair of Board
Business and Scientific expertise Entrepreneur and Scientific expertise
Novartis Pharma Orion Pharma
Clinical Research Service Turku EPID Research, University of Turku
Marko Suomela (20%), Member of Sanna Ström, Quality Manager
Board Data Management and Process expertise
Financial expertise Clinical Research Services Turku
Forex, Nestle
Tuomas Kemppainen, Expert Statistician Elina Niskanen, Marketing and Sales Director
Scientific and Process expertise Marketing and sales expertise
Novartis Pharma, 4Pharma Galanthia, admescope, John Wiley & Sons
StatFinn Ltd
 Founded in 2005 and has been profitable ever since.
 Providing data management and statistical reporting services for
various sectors in life science.
 The company has 12 employees at two offices in Turku and in
Helsinki.
The fastest way to conclusion

8. Money Talk
The investment opportunity
StatFinn is seeking for 3 million euros investment for
 organic growth and developing new report engines (eBESTpk, eBESTstab,
etc.) to strengthen service portfolio
 a company acquisition to expand market presence, and to increase
resources and revenues
 a company acquisition to expand service portfolio to fulfil the market
demand and access wider markets and deals
Previous financial rounds
 Centre for Economic Development, Transport and the Environment: 50 k€
 Product development by TEKES in 2010: 100 k€
 NIY by TEKES in 2011: 250 k€ (NIY1)  750 k€ (NIY2)
The fastest way to conclusion

9. Money Talk
The investment opportunity
Exit in 3 to 5 years with trade sale or IPO
 Unique products with clear customer benefits in growing markets
which guarantees competitive advantage and revenue with high
profit.
 Experienced team with supplementary skill combination.
 Proven business model with profitable business since its foundation.
 Reduced investment risk with successful grants approval in
investments for internationalization and development activities.
The fastest way to conclusion

10. Thank You
Contact
Pekka Heikkilä, CEO
pekka.heikkila@statfinn.fi
+358 50 321 6006
Linnankatu 9b A1, 20110 Turku
The fastest way to conclusion